One Day Advisor

An in-depth review and analysis of biopharma research and development investments based on recent industry reports. 📌 Key Takeaways: 2025 Pharma R&D Landscape Widespread Budget Tightening: 6 out of the top 10 drugmakers reduced their R&D spending in 2025 compared to 2024, with cuts ranging up to 28.9%. Merck Retains Top Spot: Despite a 12% drop in spending ($15.79B), Merck led all competitors, driven by continued Keytruda protection strategy and clinical expansion. Eli Lilly’s Metoric Surge: Fueled by massive weight-loss sales (tirzepatide), Eli Lilly boosted its R&D budget by 21.4% to $13.34B, climbing two spots up the ladder. Heavy M&A Offsets Internal Cuts: Major players like Johnson & Johnson leaned into high-value acquisitions (e.g., $14.6B buyout of Intra-Cellular) while trimming internal trial pipelines. The pharmaceutical industry experienced significant volatility in 2025. Between shifting re...

Last Updated: July 2026   This article has been updated with the latest global stock market trends, including artificial intelligence, semiconductor growth, healthcare innovation, and global economic developments. Investors searching for the best stocks to buy in 2026 face a rapidly changing investment landscape. Artificial intelligence (AI), semiconductor innovation, healthcare transformation, cloud computing, automation, and demographic changes are reshaping global markets. The next decade is likely to be defined by companies that control critical infrastructure: AI computing power, semiconductor manufacturing, digital platforms, healthcare innovation, and essential consumer services. This updated Top 10 Stocks to Buy and Hold in 2026 list provides a global portfolio of high-quality companies with strong competitive advantages, long-term growth potential, and durable business models. The selection includes market leaders across the United States, Taiwan, South Korea, a...

The global healthcare landscape has shifted dramatically. Driven by historic breakthroughs in metabolic health (the GLP-1 weight-loss boom) and massive deployments of predictive AI models in early-stage research, the world's leading drugmakers have rewritten the financial leaderboard. Below is the definitive tracking analysis of the top 20 pharmaceutical companies by annual global revenue based on verified full-year corporate reports, supplemented with live ecosystem data tracking market valuations. 🔴 Live TradingView Market Quotes Feeder The dynamic feed below communicates directly with public market data streams to show changing valuation, price movements, and market caps across major active biomedical stocks in 2026. Interactive Top 20 Revenue, Growth & Valuation Explorer Use the filtering and sorting dashboard below to isolate specific clinical focus regions and rank companies instantl...

The 10 largest publicly traded food and beverage companies by full-year 2025 revenue are: Nestlé (~$115.4B), Ahold Delhaize (~$107B), PepsiCo ($93.9B), JBS ($86.2B), Sysco ($81.4B), ADM ($80.3B), Performance Food Group ($63.3B), Anheuser-Busch InBev ($59.3B), Unilever (~$58.5B), and Tyson Foods ($54.4B). Privately held Cargill (~$160B) and Mars (~$50B+) are excluded because they don't publish standardized public financials. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, GLP-1 drug demand shifts, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This June  2026 update revises our rankings using confirmed full-year 2025 results...